Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352143 · ClinicalTrials.gov registry record
Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 24
- Enrollment target
NCT01352143: Completed study, sponsored by Emory University.
NCT01352143 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01352143 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The primary goal of this investigation is to determine the ability of recombinant activated factor VII (rFVIIa) and prothrombin complex concentrate (PCC) to improve thrombin generation in neonatal plasma after CPB.
Primary Outcome
The primary outcome measure is the peak amount of thrombin generated (measured in nM) as determined by the Thrombinoscope with rFVIIa as compared to PCC.
Interventions
- DRUG Recombinant activated factor VII
- DRUG Prothrombin Complex Concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-06 |
What the finished NCT01352143 record still lists
NCT01352143 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Recombinant activated factor VII is the first listed.
NCT01352143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01352143 about?
NCT01352143 is a clinical study titled "Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass". The primary goal of this investigation is to determine the ability of recombinant activated factor VII (rFVIIa) and prothrombin complex concentrate (PCC) to improve thrombin generation in neonatal plasma after CPB.
What is the current status of trial NCT01352143?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2011-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01352143?
The interventions under investigation include: Recombinant activated factor VII (DRUG), Prothrombin Complex Concentrate (DRUG).
Who is sponsoring clinical trial NCT01352143?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia